PIK3CA and head and neck squamous cell carcinoma: Two phase II clinical trials, including to date 47 patients, are currently evaluating the clinical efficacy of alpelisib as monotherapy in HPV-positive HNSCC (NCT03601507) and alpelisib in combination with the farnesyltransferase inhibitor tipifarnib in HRAS- and PIK3CA-mutant HNSCC (NCT04997902; 129).